Tapering and Discontinuation of Biologics in Patients with Psoriatic Arthritis with Low Disease Activity
- 61 Downloads
The introduction of biologic disease modifying anti-rheumatic drugs (bMDARDs) have revolutionised the treatment of psoriatic arthritis (PsA). This combined with a ‘treat-to-target’ approach, means that achieving remission is increasingly possible. In patients with well-controlled PsA, there is little consensus on whether bDMARDs should be continued, tapered or discontinued altogether. Tapering or discontinuation of bDMARDs could offer significant financial savings and minimise patient burden and unwanted drug-related side effects. However, there is a risk of loss of remission. The primary focus of this paper is to review the current evidence on bDMARD tapering and discontinuation in PsA. We explore the criteria employed by studies to define patients eligible for bDMARD tapering or discontinuation and the process by which this occurs. We also review the outcomes of bDMARD tapering and discontinuation, the predictors, and the likelihood of restoring remission following relapse. To date, bDMARD tapering seems to be feasible and safe in patients with PsA who are in remission or with low disease activity. Lower disease activity prior to tapering seems to increase the likelihood of successful bDMARD tapering. In contrast, discontinuing bDMARDs appears to carry a substantial risk of loss of remission. Those with higher disease activity at time of tumour necrosis factor inhibitors discontinuation, current smokers, male sex, increased skin involvement, and synovial hypertrophy seen on ultrasound prior to discontinuation are at greater risk of losing remission post-bDMARD discontinuation. In those who lose remission, reinstating the standard dose of bDMARD appears to be effective in restoring remission.
Compliance with Ethical Standards
Weiyu Ye is an academic foundation trainee. Laura J Tucker is funded by the Norman Collisson Foundation as a Clinical Research Fellow. Laura C Coates is funded by a National Institute for Health Research Clinician Scientist award. The research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
Conflict of interest
Laura C Coates has received research funding and/or honoraria from Abbvie, Amgen, BMS, Celgene, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Prothena and UCB. Weiyu Ye and Laura J Tucker have no conflicts of interest to disclose.
- 4.NICE [TA199]. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. 2010. https://www.nice.org.uk/guidance/ta199. Accessed 25 September 2018.
- 7.Herwaarden N, Broeder AA, Jacobs W, Maas A, Bijlsma JWJ, Vollenhoven RF, Bemt BJF. Down-titration and discontinuation strategies of tumor necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev. 2014. https://doi.org/10.1002/14651858.cd010455.pub2.CrossRefPubMedGoogle Scholar
- 8.Henaux S, Ruyssen-Witrand A, Cantagrel A, Barnetche T, Fautrel B, Filippi N, et al. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Ann Rheum Dis. 2018;77(4):515–22.CrossRefGoogle Scholar
- 15.Lόpez-Vives PV, Estrada I, Martín-Esteve M, Aparicio X, Juanola JM, Nolla J Rodríguez-Moreno. Dose reduction and/or withdrawal of anti-TN treatment in psoriatic arthritis. Annal Rheum Dis. 2012;71(3):108–9.Google Scholar
- 18.J B, Anton R, Navarro Ruiz A, Castera M, Jd R, A M. Persistence and econ”mic impact of etanercept and adalimumab dose reduction in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients with at least 1 year in clinical remission: experience from 2 Spanish teaching hospitals during 5 years of follow-up. Value Health. 2015;18:A643 [abstract].CrossRefGoogle Scholar
- 21.Moverley A, Coates L, Marzo-Ortega H, Waxman R, Torgerson D, Cocks K, et al. A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis (REmoval of treatment for patients in REmission in psoriatic ArThritis (RETREAT (F)). Clin Rheumatol. 2015;34(8):1407–12.CrossRefGoogle Scholar
- 26.González-Álvaro I, Martínez-Fernández C, Dorantes-Calderón B, García-Vicuña R, Hernández-Cruz B, Herrero-Ambrosio A, et al. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford). 2015;54(7):1200–9.CrossRefGoogle Scholar
- 28.ReDOSER calculator. http://redoser.ser.es/#!/. Accessed 1 Oct 2018.